“The data proves it works for Covid, the FDA know it works for Covid. It revealed a benefit when used WITH the SOC.”

The FDA is not going to approve a drug based on post hoc analysis. Now, had the 75% analysis been conducted, endpoints and enrollment adjusted and then we are successful, sure, EUA tomorrow. But CYDY felt the need to rush the trial to completion and now we need another trial. Good news is the trial is only 140 patients and will enroll quickly and the 18 established sites.